Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotór (rak gruczołowy) prostaty
- •Rak rozprzestrzenił się na inne części ciała (przerzuty)
- •Poprzednio leczony hormonalnie z potwierdzonym niskim poziomem testosteronu
- •Choroba pogorszyła się mimo wcześniejszego leczenia abirateronem
- •Poziom PSA (markera raka) co najmniej 1,0 ng/ml
- •Dobra funkcja wątroby, nerek i układu krwiotwórczego
- •Stan ogólny pacjenta pozwala na leczenie (ECOG ≤2)
✗ Disqualifies
- •Poprzednie leczenie enzalutamidą, apolutamidą lub podobnymi lekami
- •Brak okresu przerwy co najmniej 2 tygodnie od przerwania abirateron
- •Pacjenci nie mogą być odstawieni z prednizonu bez objawów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- July 17, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (6)
University of California, San Diego (UCSD)
San Diego, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Dana-Faber Cancer Institute
Boston, United States
University of Minnesota
Minneapolis, United States
University of Nebraska Medical Center
Omaha, United States
University of Washington/Fred Hutchinson Cancer Center
Seattle, United States
Trial contact
Harry Cao, MA
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.